Achieve Life Sciences insider: 69,000 PRSU shares settled, 20,854 sold for taxes
Rhea-AI Filing Summary
Achieve Life Sciences insider report: Jaime Xinos, the company's Chief Commercial Officer and a director, reported transactions dated 09/04/2025. He received 69,000 shares of common stock upon settlement of performance restricted stock units (PRSUs) and the issuer sold 20,854 shares to cover income tax withholding at a weighted average price of $2.77 per share. After these transactions he beneficially owned 74,432 shares. The Form 4 also shows outstanding PRSUs: 49,000 that vest upon achievement of certain milestones (settlement date tied to 01/22/2028) and 20,000 PRSUs with a measurement period extending to 01/28/2035 that may vest 0%–100% depending on performance. The form was filed by an attorney-in-fact on 09/08/2025.
Positive
- Settlement of PRSUs for 69,000 shares increases insider ownership and aligns management with shareholder interests
- Large performance-based awards (49,000 and 20,000 PRSUs) indicate compensation tied to clearly defined milestones and long-term performance
Negative
- 20,854 shares sold to satisfy tax withholding reduced the immediate net share increase from the PRSU settlement
- Potential dilution from outstanding PRSUs which may vest up to 100% for the 20,000-unit tranche through 2035
Insights
TL;DR: Executive received a large PRSU payout and sold shares to cover taxes, leaving modest net ownership.
The settlement of 69,000 shares increases insider alignment with shareholders but the net addition is smaller after the tax-related disposition of 20,854 shares at a weighted average of $2.77. Post-transaction beneficial ownership of 74,432 shares is disclosed. The presence of additional PRSUs (49,000 and 20,000) with milestone-based and measurement-period vesting schedules indicates future potential dilution contingent on performance. These are routine compensation-related transactions and no open-market purchase for investment is reported.
TL;DR: Compensation settlement and tax withholding sale reflect standard equity award administration, not a management exit signal.
The report documents earned performance awards certified by the Compensation Committee and their settlement into common shares. The simultaneous net settlement and tax-withholding sale are typical mechanics of PRSU settlements. The filing does not show any departures, change-in-control considerations, or unusual insider dispositions. Vesting conditions and long measurement windows for a tranche through 2035 suggest multi-year performance alignment.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Restricted Stock Unit (PRSU) | 49,000 | $0.00 | -- |
| Exercise | Performance Restricted Stock Unit (PRSU) | 20,000 | $0.00 | -- |
| Exercise | Common Stock | 69,000 | $0.00 | -- |
| Sale | Common Stock | 20,854 | $2.77 | $58K |
Footnotes (1)
- Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II. Represents shares of common stock that have been sold by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PRSUs. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $2.88 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones. Represents PRSUs previously reported on January 30, 2025 that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors. Pursuant to the terms of the award agreement governing the PRSU, the number of underlying shares of the Issuer's common stock that may ultimately vest ranges from 0% to 100% of the number of the PRSUs initially granted, subject to certain milestones being met during the measurement period.
